Management of Brain and Spine Metastases in Community Practice
This session reviews the recent data for the sequence and timing of targeted therapies and immune checkpoint inhibitors and radiation therapy for patients with brain metastases. The speakers consider radiation therapy options for patients with large volume or multiple brain metastases, as well as patients with oligometastatic disease. The session also examines techniques, treatment volumes and normal tissue constraints for spine SBRT.
Topics:
- Management of Brain Metastases With Targeted Therapy
Lindsey Sloan, MD, PhD - Management of Large Volume or Multiple Brain Metastases
Tony J. C. Wang, MD - Management of Spine Metastases With SBRT
Kristin J. Redmond, MD, MPH - Q&A
This activity is available from June 27, 2023, through 11:59 p.m. Eastern time on June 26, 2025.
This activity was originally recorded at the 2022 ASTRO Annual Meeting Practical Radiation Oncology Program.
Target Audience
The activity is designed to meet the interests of radiation oncologists.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify appropriate radiation treatment modalities for treatment of patients with oligometastases or multiple metastases to the brain, in the setting of targeted therapy.
- Assess the application of spine SBRT (treatment volumes, dose, normal tissue constraints) for patients with spine metastases.
Christine S. Chung, MD, is employed by John Muir Medical Center.
Lindsey Sloan, MD, PhD, is employed by the University of Minnesota and receives compensation from Medtronic and Sanofi as an Advisory Board member.
Tony J. C. Wang, MD, is employed by Columbia University Irving Medical Center and receives compensation from Abbvie, AstraZeneca, Cancer Panels, Doximity, Elekta, Genentech, Iylon Precision Oncology, Merck, Novocure, RTOG Foundation, Rutgers, University of Iowa, Varian, and Wolters Kluwer. Dr. Wang owns stock options with Doximity.
Kristin J. Redmond, MD, MPH, is employed by Johns Hopkins University and receives compensation from Accuray, AstraZeneca, BioMimetix, Brainlab, Elekta AB, icotec, and NCCN. Dr. Redmond serves in a leadership role for ASTRO and Camp Kesem.
Virginia M, Diavolitsis, MD, is employed by The Ohio State University.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until June 26, 2025, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.